SanBio (SNBIF) Stock Price, News & Analysis

Company Overview

SanBio Inc. is a clinical‐stage regenerative medicine company focused on developing proprietary cell therapies to address central nervous system disorders. The company’s core technology is based on modulating the brain’s innate repair mechanisms through the transplantation of adult stem cells, with the goal of restoring neurological function in patients suffering from conditions such as stroke, traumatic brain injury and neurodegenerative diseases.

The company’s lead product candidate, SB623, is an investigational cell therapy for chronic motor deficits following ischemic stroke. SB623 has advanced through multiple Phase II clinical studies, demonstrating potential improvements in motor function and quality of life for affected patients. In addition to SB623, SanBio’s pipeline includes SB618 for traumatic brain injury and other earlier‐stage programs targeting additional neurological indications. SanBio has entered into licensing agreements with pharmaceutical partners to support development and commercialization, including arrangements for rights in key Asian markets.

Headquartered in Tokyo, Japan, with research operations in the United States, SanBio leverages an international footprint to conduct clinical trials and collaborate with academic and industry partners. The company was founded to translate decades of neuroscientific research into practical therapies for patients with limited treatment options. SanBio’s management team is composed of professionals with experience in biotechnology development, clinical research and regulatory affairs, guiding the company through its clinical‐stage programs toward potential commercialization.

Key Stats

• Today's Range: C$10.11 to C$10.11
• 50-Day Range: C$10.11 to C$10.11
• 52-Week Range: C$4.65 to C$23.00
• Volume: N/A
• Average Volume: 417 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:SNBIF
• CIK: N/A
• Web: www.sanbio.jp
• Phone: 81 3 6264 3481
• Fax: N/A
• Employees: 29
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A